Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0851
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy ; volume:68 ; number:8 ; day:18 ; month:6 ; year:2019 ; pages:1235-1243 ; date:8.2019
Cancer immunology immunotherapy ; 68, Heft 8 (18.6.2019), 1235-1243, 8.2019
- Creator
-
Mensali, Nadia
Myhre, Marit Renée
Dillard, Pierre
Pollmann, Sylvie
Gaudernack, Gustav
Kvalheim, Gunnar
Wälchli, Sébastien
Inderberg, Else Marit
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-019-02356-2
- URN
-
urn:nbn:de:101:1-2020041405480300765906
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mensali, Nadia
- Myhre, Marit Renée
- Dillard, Pierre
- Pollmann, Sylvie
- Gaudernack, Gustav
- Kvalheim, Gunnar
- Wälchli, Sébastien
- Inderberg, Else Marit
- SpringerLink (Online service)
Other Objects (12)
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
TCR engineered T cells for solid tumor immunotherapy
TCR-like antibodies in cancer immunotherapy
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
TCR diversity – a universal cancer immunotherapy biomarker?
Next-Generation TCR-transgenic T cells for Immunotherapy
RNAi-mediated knockdown of the endogenous TCR improves safety of immunotherapy with TCR gene-modified T cells
Imaging of tumour response to immunotherapy
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
HNSCC: tumour antigens and their targeting by immunotherapy
Combining effects of one tumor-stroma recognizing TCR with one cancer‑cell specific TCR for eradication of solid tumors
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
TCR engineered T cells for solid tumor immunotherapy
TCR-like antibodies in cancer immunotherapy
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
TCR diversity – a universal cancer immunotherapy biomarker?
Next-Generation TCR-transgenic T cells for Immunotherapy
RNAi-mediated knockdown of the endogenous TCR improves safety of immunotherapy with TCR gene-modified T cells
Imaging of tumour response to immunotherapy
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
HNSCC: tumour antigens and their targeting by immunotherapy
Combining effects of one tumor-stroma recognizing TCR with one cancer‑cell specific TCR for eradication of solid tumors
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
TCR engineered T cells for solid tumor immunotherapy
TCR-like antibodies in cancer immunotherapy
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
TCR diversity – a universal cancer immunotherapy biomarker?
Next-Generation TCR-transgenic T cells for Immunotherapy
RNAi-mediated knockdown of the endogenous TCR improves safety of immunotherapy with TCR gene-modified T cells
Imaging of tumour response to immunotherapy
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
HNSCC: tumour antigens and their targeting by immunotherapy